Home

COMIRNATY:
The first
FDA-approved
COVID-19 vaccine6

The first mRNA
COVID-19 vaccine stored at REFRIGERATED TEMPERATURE supplied in a single dose glass prefilled syringe4,7,8

May be stored for up to 8 months in refrigerator from date of manufacture. Do not exceed the expiration date printed on the carton and syringe4,8

COMIRNATY® (COVID-19 Vaccine, mRNA) packaging and glass prefilled syringes COMIRNATY® (COVID-19 Vaccine, mRNA) packaging and glass prefilled syringes

Store COMIRNATY glass prefilled syringes refrigerated at 2°C to 8°C (35°F to 46°F).
DO NOT FREEZE4,8

Help protect eligible patients 12 years of age and older against COVID-19 with COMIRNATY4

Find Out About Dosing and Preparation

Your recommendation matters

Discussing COVID-19
vaccination with eligible
patients can be an important

first step in helping to protect
them against COVID-199

COVID-19=coronavirus disease 2019; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.

Ordering available through Pfizer Prime*

Orders for 2024-2025 formula COVID-19 vaccines by BioNTech and Pfizer can be placed by eligible
healthcare professionals directly with Pfizer through Pfizer Prime online or by calling 1-800-533-4535.

Visit Pfizer Prime

*Eligible healthcare providers can order COVID-19 vaccines directly from
Pfizer. If preferred, orders may be placed with your facility’s wholesaler.

IMPORTANT SAFETY INFORMATION

Do not administer COMIRNATY® (COVID-19 Vaccine, mRNA) to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of COMIRNATY or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of a Pfizer-BioNTech COVID-19 vaccine.

Management of Acute Allergic Reactions

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of COMIRNATY.

Myocarditis and Pericarditis

Postmarketing data with authorized or approved mRNA COVID-19 vaccines demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following vaccination. For COMIRNATY, the observed risk is highest in males 12 through 17 years of age. Although some cases required intensive care support, available data from short-term follow-up suggest that most individuals have had resolution of symptoms with conservative management. Information is not yet available about potential long-term sequelae.

The Centers for Disease Control and Prevention (CDC) has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html).

Syncope

Syncope (fainting) may occur in association with administration of injectable vaccines, including COMIRNATY. Procedures should be in place to avoid injury from fainting.

Altered Immunocompetence

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to COMIRNATY.

Limitation of Vaccine Effectiveness

COMIRNATY may not protect all vaccine recipients.

Adverse Reactions

The most commonly reported adverse reactions (≥10%) after a dose of COMIRNATY were pain at the injection site (up to 90.5%), fatigue (up to 77.5%), headache (up to 75.5%), chills (up to 49.2%), muscle pain (up to 45.5%), joint pain (up to 27.5%), fever (up to 24.3%), injection site swelling (up to 11.8%), and injection site redness (up to 10.4%).

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or https://www.pfizersafetyreporting.com or VAERS at 1-800-822-7967 or http://vaers.hhs.gov

Please click for COMIRNATY Full Prescribing Information and Patient Information.

INDICATION

COMIRNATY® (COVID-19 Vaccine, mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.

Expand

For more information

Headset Icon
Pfizer Customer
Service

Including General Product Questions.

Call 1-800-879-3477
Information Icon Medical
Information
Visit PfizerMedicalInformation.com
Globe Icon Shipment Support
US Trade Customer Service
Call 1-800-666-7248
Headset Icon

Pfizer Customer Service

Including General
Product Questions.

Call 1-800-879-3477

Information Icon

Medical Information

Visit
PfizerMedicalInformation.com

Globe Icon

Shipment Support US Trade Customer Service

Call 1-800-666-7248

Text Updates Icon Get COVID-19 Vaccine
Text Updates Enroll in the BioNTech & Pfizer COVID Connect text messaging program for U.S. Healthcare Professionals.
Phone Icon Call a Pfizer Connect
Representative Live representatives are available 9 AM–5 PM ET to help HCPs answer product questions, discuss Pfizer Prime ordering, and more.
Call 1-844-966-5127
References: Reference: References
  1. COVID-19 vaccinations in the United States, jurisdiction. Centers for Disease Control and Prevention. Updated May 12, 2023. Accessed April 16, 2025. https://data.cdc.gov/Vaccinations/COVID-19-Vaccinations-in-the-United-States-Jurisdi/unsk-b7fc/about_data
  2. IQVIA National Prescription Audit, retail (September 2023-January 2025).
  3. IQVIA National Prescription Audit and Drug Distribution Data (September 2023-January 2025).
  4. COMIRNATY® (COVID-19 Vaccine, mRNA). Prescribing Information. BioNTech Manufacturing GmbH and Pfizer Inc.; October 18, 2024.
  5. CDC COVID-19 vaccine administration and distribution data. Jurisdiction abbreviations: COVID-19 vaccinations in the United States, jurisdiction. Centers for Disease Control and Prevention. Updated May 4, 2023. Accessed April 28, 2025. https://data.cdc.gov/api/views/unsk-b7fc/files/cec0661b-25b0-4fd8-9988-c138b4f2ad16?download=true&filename=DataDictionary_v37_05052023.xlsx
  6. FDA approves first COVID-19 vaccine. US Food and Drug Administration. Updated August 23, 2021. Accessed April 16, 2025. https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine
  7. Moderna COVID-19 vaccine summary. Centers for Disease Control and Prevention. Updated August 28, 2024. Accessed April 15, 2025. https://www.cdc.gov/vaccines/php/info-by-product/moderna-COVID-19-summary.html
  8. Pfizer COVID-19 vaccine summary. Centers for Disease Control and Prevention. Updated August 28, 2024. Accessed April 15, 2025. https://www.cdc.gov/vaccines/php/info-by-product/pfizer-covid-19-summary.html
  9. Talking with patients about COVID-19 vaccination: an introduction to motivational interviewing for healthcare professionals. Centers for Disease Control and Prevention. Updated November 3, 2021. Accessed April 15, 2025. https://www.cdc.gov/vaccines/covid-19/hcp/engaging-patients.html